The closing price of Taysha Gene Therapies Inc (NASDAQ: TSHA) was $2.58 for the day, down -3.20% from the previous closing price of $2.66. On the day, 1475308 shares were traded.
Ratios:
Our analysis of TSHA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.06. In the meantime, Its Debt-to-Equity ratio is 0.82 whereas as Long-Term Debt/Eq ratio is at 0.79.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on April 09, 2024, initiated with a Overweight rating and assigned the stock a target price of $9.
On February 01, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $14 to $1.50.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 27, 2023, whereas the target price for the stock was revised from $23 to $3.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’23 when Manning Paul B bought 100,000 shares for $1.63 per share. The transaction valued at 163,000 led to the insider holds 16,566,667 shares of the business.
Alam Kamran sold 33,000 shares of TSHA for $76,890 on Aug 24 ’23. The Chief Financial Officer now owns 258,042 shares after completing the transaction at $2.33 per share. On Aug 16 ’23, another insider, Manning Paul B, who serves as the 10% Owner of the company, bought 16,466,667 shares for $0.90 each. As a result, the insider paid 14,820,000 and bolstered with 16,466,667 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 31.17 while its Price-to-Book (P/B) ratio in mrq is 6.42.
Stock Price History:
Over the past 52 weeks, TSHA has reached a high of $3.89, while it has fallen to a 52-week low of $0.50.
Shares Statistics:
A total of 186.96M shares are outstanding, with a floating share count of 128.62M. Insiders hold about 31.23% of the company’s shares, while institutions hold 62.25% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 10 analysts. On average, analysts expect EPS of -$0.11 for the current quarter, with a high estimate of -$0.07 and a low estimate of -$0.19, while EPS last year was -$0.28. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.08 and low estimates of -$0.2.
Analysts are recommending an EPS of between -$0.3 and -$0.57 for the fiscal current year, implying an average EPS of -$0.41. EPS for the following year is -$0.48, with 9 analysts recommending between -$0.35 and -$0.63.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 9 analysts. It ranges from a high estimate of $4.5M to a low estimate of –$. As of the current estimate, Taysha Gene Therapies Inc’s year-ago sales were $4.71M, an estimated decrease of -45.60% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $2.57M, an increase of 7.30% over than the figure of -$45.60% in the same quarter last year. There is a high estimate of $4.5M for the next quarter, whereas the lowest estimate is –$.
A total of 9 analysts have provided revenue estimates for TSHA’s current fiscal year. The highest revenue estimate was $18.1M, while the lowest revenue estimate was –$, resulting in an average revenue estimate of $10.24M. In the same quarter a year ago, actual revenue was $15.45M, down -33.70% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $5.72M in the next fiscal year. The high estimate is $15M and the low estimate is –$. The average revenue growth estimate for next year is down -44.10% from the average revenue estimate for this year.
